Novel agents under investigation in MPNs: MDM2, XPO1, and BET inhibitors 

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses novel agents under investigation for treating myeloproliferative neoplasms (MPNs), including MDM2 inhibitors, XPO1 inhibitors, and BET inhibitors. The efficacy and approval of these agents are still to be determined. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.